Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic medical device company announced an expansion of its management team to support its recent regulatory milestones and commercial success. New hires include Anne-Marie Ripley, Vice President of Clinical and Regulatory Affairs, Ingrid Kane, M.D., Vice President of Global Medical Affairs, Jamie Chakales, Vice President of Global Sales and Marketing, John Ordway, Vice President of Manufacturing and Operations, and Richard Rush, Vice President of Quality Assurance.
“Now with the expansion of our strong leadership team that brings substantial clinical, operational, and commercial expertise to Sight Sciences, we are ready to execute effectively on our strategic commercial goals and company milestones in 2017 and beyond.”
“I am pleased to announce the most recent additions to the Sight Sciences leadership team,” states Paul Badawi, CEO of Sight Sciences. “Our lean founding technical team has done an exceptional job over the years inventing new products and new solutions that position us for clinical and commercial success in the fastest growing ophthalmology and optometry markets. Now with the expansion of our strong leadership team that brings substantial clinical, operational, and commercial expertise to Sight Sciences, we are ready to execute effectively on our strategic commercial goals and company milestones in 2017 and beyond.”
“I am proud to be a part of this truly innovative ophthalmic medical device company comprised of a talented team of seasoned medical device experts,” states Anne-Marie Ripley, Vice President of Clinical and Regulatory Affairs at Sight Sciences who brings over 20 years of success working in medical device companies. Anne-Marie is the former Vice President of Clinical and Regulatory Affairs at Second Sight Medical Products, a spin-out from the Alfred Mann Foundation. At Second Sight, Anne-Marie successfully guided the world’s first retinal prosthesis through successful clinical trials and FDA approval. “I look forward to introducing the cutting-edge Sight Sciences technologies and procedures to the global ophthalmic and optometric communities.”
In addition to Anne-Marie Ripley, other senior additions to the Sight Sciences team include:
Ophthalmic medical expert, Ingrid Kane M.D., Vice President of Global Medical Affairs. Dr. Kane was the former Vice President of Medical Affairs at AqueSys, iScience Interventional and Ellex. Dr. Kane has introduced and personally trained surgeons in over 25 countries on new injectable therapeutics, medical devices, and surgeries for ophthalmic conditions ranging from glaucoma to diabetic macular edema.
Seasoned commercial executive, Jamie Chakales, Vice President of Global Sales and Marketing. Jamie brings over two decades of commercial leadership experience and has successfully introduced a variety of disruptive ophthalmic and cardiovascular medical devices to the surgical community for companies such as Allergan, Guidant, Ellex and iScience Interventional. Most recently, Jamie was instrumental in introducing the world to ab externo canaloplasty, a surgical procedure for the treatment of glaucoma.
Experienced medical device manufacturing and operations executive, John Ordway, Vice President of Manufacturing and Operations. John brings over 25 years of experience in medical device manufacturing, supply chain, and operations management from companies including Moximed, Kyphon, AngioScore, St. Francis Technologies, and Guidant. He has successfully scaled up each of his venture-backed medical device companies from limited early production to full-scale, high volume manufacturing.
Veteran quality management executive, Richard Rush, Vice President of Quality Assurance. Richard brings over 20 years of medical device quality management expertise. Richard’s previous experiences include senior management roles at Alcon, Guidant and Coherent.
About Sight Sciences: Sight Sciences is a medical device company serving the ophthalmic and optometric communities and dedicated to the development of technology-driven solutions that address the underlying physiology of eye diseases. The company operates two business lines: surgical and non-surgical devices. Its surgical product portfolio consists of the TRAB™360 and VISCO™360 surgical devices. Its non-surgical product portfolio consists of the TearCare™ product line which delivers targeted thermal energy to the meibomian glands in the eyelids. For more information, visit www.sightsciences.com.
Read Full Article